Bilimsel çalışmalar

Doç. Dr. Burçin Çakan Demirel

61 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062406 PMID 41899326 Açık erişimli tam metinKaynak: OpenAlex

  2. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy

    Pharmaceuticals, 2026

    DOI 10.3390/ph19040587 PMID 42075843 Açık erişimli tam metinKaynak: OpenAlex

  3. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15083118 PMID 42074920 Açık erişimli tam metinKaynak: OpenAlex

  4. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

    OncoImmunology, 2026

    DOI 10.1080/2162402x.2026.2738262 PMID 42788839 Açık erişimli tam metinKaynak: OpenAlex

  5. Real-world Efficacy and Safety of Trastuzumab Deruxtecan in HER2-positive Metastatic Breast Cancer: A Multicenter Retrospective Study from Türkiye

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-1-1 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  6. The Impact of the Systemic Immune-inflammation Index and the Systemic Inflammatory Response Index on Progression-free Survival and Overall Survival in Second-line Immunotherapy for Metastatic Non-small Cell Lung Cancer

    Bagcilar Medical Bulletin, 2026

    DOI 10.4274/bmb.galenos.2026.70299 Açık erişimli tam metinKaynak: OpenAlex

  7. Prognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15166326 PMID 42652730 Açık erişimli tam metinKaynak: OpenAlex

  8. Prognostic Value of Systemic Inflammatory Markers in Locally Advanced or Metastatic Melanoma: A Real-World Analysis

    Cancers, 2026

    DOI 10.3390/cancers18030420 PMID 41681891 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  9. Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15051898 PMID 41827314 Açık erişimli tam metinKaynak: OpenAlex

  10. Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062217 PMID 41899145 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  11. Clinicopathological Predictors of Axillary Pathological Complete Response and Its Prognostic Significance in Clinically Node-Positive (cN+), HER2-Positive Breast Cancer Following Neoadjuvant Therapy

    Medicina, 2026

    DOI 10.3390/medicina62010200 PMID 41597486 Açık erişimli tam metinKaynak: OpenAlex

  12. Differential Metastatic Patterns and Prognostic Value of Systemic Inflammation Scores in Anaplastic Lymphoma Kinase Rearranged Versus Anaplastic Lymphoma Kinase Negative Non-Small Cell Lung Cancer

    Cancers, 2026

    DOI 10.3390/cancers18030501 PMID 41681973 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  13. Meme Kanseri

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852 Açık erişimli tam metinKaynak: OpenAlex

  14. Role of Prognostic Nutritional Index and C-Reactive Protein/Albumin Ratio in Prognosis of Locally Advanced Nasopharyngeal Carcinoma

    Medicina, 2026

    DOI 10.3390/medicina62020377 PMID 41752776 Açık erişimli tam metinKaynak: OpenAlex

  15. Association of Post-Neoadjuvant Chemotherapy MRI and 18F-FDG PET/CT Findings with Tumor Response and Prognosis in Breast Cancer

    Diagnostics, 2026

    DOI 10.3390/diagnostics16050713 PMID 41827989 Açık erişimli tam metinKaynak: OpenAlex

  16. Inflammation-tumor burden interaction score stratifies survival after irinotecan-eluting bead chemoembolization for colorectal liver metastases

    Frontiers in Medicine, 2026

    DOI 10.3389/fmed.2026.1751660 PMID 41907246 Açık erişimli tam metinKaynak: OpenAlex

  17. Determinants of survival after neoadjuvant chemotherapy in resectable gastric cancer: adjuvant dose intensity, radiotherapy, and pathologic response

    Expert Review of Anticancer Therapy, 2026

    DOI 10.1080/14737140.2026.2657911 PMID 41950348 Kaynak: OpenAlex

  18. Association of Pretreatment Immune-Inflammatory Biomarkers with Pathological Tumor Regression Following Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15135039 PMID 42452500 Açık erişimli tam metinKaynak: OpenAlex

  19. Pathological Response and Survival Outcomes Following Neoadjuvant Chemotherapy in HR+/HER2- Breast Cancer: Real-world Experience

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-3-9 Açık erişimli tam metinKaynak: OpenAlex

  20. Radiotracer-Free Axillary Staging with ICG and Methylene Blue After Neoadjuvant Chemotherapy: Does Failure to Retrieve the Clipped Node Matter?

    Cancers, 2026

    DOI 10.3390/cancers18162550 PMID 42649865 Açık erişimli tam metinKaynak: OpenAlex

  21. Comparative Prognostic Value of Systemic Inflammation-Based Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with First-Line Immunotherapy

    Biomedicines, 2026

    DOI 10.3390/biomedicines14081825 PMID 42652206 Açık erişimli tam metinKaynak: OpenAlex

  22. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Clinical Breast Cancer, 2025

    DOI 10.1016/j.clbc.2025.03.003 PMID 40190010 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  23. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1639022 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  24. A multi-center case-control study on osteoporosis risk in cancer patients receiving chemotherapy.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.12033 Kaynak: OpenAlex

  25. Prognostic Value of a New Marker, IBI Score and NLR Change in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (Prognostic value of IBI score and NLR change in NSCLC)

    Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi, 2025

    DOI 10.47572/muskutd.1603917 Açık erişimli tam metinKaynak: OpenAlex

  26. The impact of SARS-CoV-2 infection on the survival in NSCLC patients undergoing immunotherapy

    Pamukkale Medical Journal, 2025

    DOI 10.31362/patd.1598359 Açık erişimli tam metinKaynak: OpenAlex

  27. A multicenter prospective matched comparative study on osteoporosis risk in cancer patients receiving chemotherapy

    Supportive Care in Cancer, 2025

    DOI 10.1007/s00520-025-09973-x PMID 41225034 1 atıf (Europe PMC) Kaynak: OpenAlex

  28. Real-World Outcomes of Treatment Approaches and the Impact of Systemic Inflammation Markers on Survival in Patients with Locally Advanced and Metastatic Laryngeal Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14248924 PMID 41464825 Açık erişimli tam metinKaynak: OpenAlex

  29. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

    BMC Cancer, 2024

    DOI 10.1186/s12885-024-13357-5 PMID 39736618 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  30. Prognostic Value of ALBI Score and Lymphocyte-Associated Inflammation Markers in Advanced Hepatocellular Carcinoma: A Single Centre Retrospective Cross-Sectional Study

    Namık Kemal Tıp Dergisi, 2024

    DOI 10.4274/nkmj.galenos.2024.93898 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  31. 223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.103245 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  32. Use of albumin and CRP related immuno-nutritional markers for prediction of locoregional response to treatment in unresectable hepatocellular carcinoma

    Pamukkale Medical Journal, 2024

    DOI 10.31362/patd.1471860 Açık erişimli tam metinKaynak: OpenAlex

  33. The Optimal Treatment Approaches and Prognostic Factors In Elderly Patients with Advanced Stage Biliary Tract Tumors

    Acta Oncologica Turcica, 2023

    DOI 10.5505/aot.2023.03708 Açık erişimli tam metinKaynak: OpenAlex

  34. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

    BMC Cancer, 2023

    DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  35. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

    Future Oncology, 2023

    DOI 10.2217/fon-2022-1287 PMID 37133230 22 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  36. Pretreatment PLR Is Preferable to NLR and LMR as a Predictor in Locally Advanced and Metastatic Bladder Cancer

    Cancer Diagnosis & Prognosis, 2023

    DOI 10.21873/cdp.10275 PMID 37927800 9 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  37. 252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study

    ESMO Open, 2023

    DOI 10.1016/j.esmoop.2023.101440 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  38. THE EFFECT OF PRE-TREATMENT INFLAMMATORY RESPONSE MARKERS ON SURVIVAL IN LOCALLY ADVANCED UNRESECTABLE AND METASTATIC GASTRIC CANCER: A RETROSPECTIVE CROSS-SECTIONAL STUDY

    Pamukkale Medical Journal, 2023

    DOI 10.31362/patd.1265291 Açık erişimli tam metinKaynak: OpenAlex

  39. PROGNOSTIC SIGNIFICANCE OF SYSTEMIC IMMUNE INFLAMMATION INDICES AND PROGNOSTIC NUTRITIONAL INDEX BEFORE CDK4/6 INHIBITOR THERAPY IN HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE METASTATIC BREAST CANCER PATIENTS

    Pamukkale Medical Journal, 2023

    DOI 10.31362/patd.1268419 Açık erişimli tam metinKaynak: OpenAlex

  40. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

    Current Medical Research and Opinion, 2022

    DOI 10.1080/03007995.2022.2108619 PMID 35916475 4 atıf (Europe PMC) Kaynak: OpenAlex

  41. The Effect of Continuing Chemotherapy after Chemoradiotherapy during the Time to Surgery on Tumor Response and Survival for Local Advanced Rectal Cancer

    Journal of Oncology, 2022

    DOI 10.1155/2022/4108677 PMID 36157223 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  42. Evaluation of Serum microRNA Let-7c and Let-7d as Predictive Biomarkers for Metastatic Pancreatic Cancer

    The Turkish Journal of Gastroenterology, 2022

    DOI 10.5152/tjg.2022.21829 PMID 35943151 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  43. Hipertansiyon Tanı ve Tedavisine Güncel Yaklaşım

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.607 Açık erişimli tam metinKaynak: OpenAlex

  44. Over kanserinde nötrofil/lenfosit, trombosit/lenfosit, crp/albümin oranları ile klinikopatolojik özellikler ve sağkalım arasındaki ilişki.

    Pamukkale Medical Journal, 2021

    DOI 10.31362/patd.907695 Kaynak: OpenAlex

  45. 7.1. Uluslararası hakemli dergilerde yayınlanan makaleler (SCI & SSCI & Arts and Humanities)

    Kaynak: medipol.com.tr profil sayfası

  46. 7.3. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler

    Kaynak: medipol.com.tr profil sayfası

  47. 7.4. Yazılan uluslararası kitaplar veya kitaplarda bölümler

    Kaynak: medipol.com.tr profil sayfası

  48. 7.7. Diğer yayınlar

    Kaynak: medipol.com.tr profil sayfası

  49. Çakan B, Açikgöz O, Bilici A, Demir T, Oven BB, Hamdard J, Olmuşçelik O, Ölmez OF, Şeker M, Yıldız Ö. Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey. JBUON. 2021;26(5):1908-1917.

    Kaynak: medipol.com.tr profil sayfası

  50. Acikgoz O, Cakan B, Demir T, et al. Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer. Medicine (Baltimore). 2021;100(44):e27712. doi:10.1097/MD.0000000000027712

    Kaynak: medipol.com.tr profil sayfası